Key result
Hemosorption matches the ~13% LVEF increase of surgical remodeling but is linked to lower mortality.
Why the study?
Despite medical advances, morbidity and mortality in dilated cardiomyopathy-related severe heart failure remain high, prompting evaluation of hemosorption versus surgical left ventricular remodeling.
Does hemosorption improve left ventricular contractility and clinical outcomes compared to surgical left ventricular remodeling in patients with severe heart failure and dilated cardiomyopathy?
Cohort (n=80)
Does hemosorption improve left ventricular contractility and clinical outcomes compared to surgical left ventricular remodeling in patients with severe heart failure and dilated cardiomyopathy?
Hemosorption may serve as a safer and effective alternative to surgical left ventricular remodeling for improving LV contractility in patients with severe heart failure due to dilated cardiomyopathy.
Answers are grounded in this paper and cite their sources.
May support hemosorption as less invasive option in DCM-HF; hypothesis-generating, requires RCTs before practice change.
Background. Currently, about 40 million people in the world suffer from heart failure (HF). The development of severe HF is most often caused by dilated cardiomyopathy (DCM) that is a frequent indication for heart transplantation worldwide. Despite significant advances in the medical treatment of this pathology, the morbidity, hospitalization rates, and mortality are constantly increasing. This study aimed to evaluate the effectiveness of hemosorption in patients with severe HF on the background of DCM compared to surgical left ventricular remodeling. Materials and methods. The study is based on the results of a retrospective study that included 80 patients with severe HF on the background of DCM (NYHA III–IV). In group 1 (59 patients; left ventricular ejection fraction (LVEF) 21.10 ± 4.66 %), conservative medical therapy was supplemented with a course of 3 hemosorption procedures using granular deligandizing hemosorbent. In group 2 (21 patients; LVEF 22.40 ± 2.27 %), patients underwent surgical interventions in the form of LV remodeling. Results. There was a significant improvement in the clinical state and LV contractility in both groups. In group 1, LVEF increased by 12.90 ± 2.06 % (p < 0.01), in group 2 — by 13.25 ± 2.98 % (p < 0.05). However, more complications, longer hospital stay, and higher mortality were associated with LV remodeling. Conclusions. The use of extracorporeal hemocorrection methods in the comprehensive treatment of patients with DCM can improve the clinical state of patients, treatment outcomes and avoid the risks associated with surgical interventions.
No takes yet. Share an insight, caveat, or question.
Denysiuk et al. (2023) conducted a cohort in Dilated cardiomyopathy and severe heart failure (n=80). Hemosorption vs. Surgical left ventricular remodeling was evaluated on Increase in left ventricular ejection fraction (LVEF). Hemosorption increased LVEF by 12.90% compared to 13.25% with surgical LV remodeling, but avoided the higher complication rates, longer hospital stays, and higher mortality of surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: